MARKET

DRRX

DRRX

DURECT
NASDAQ
0.7300
+0.0740
+11.28%
After Hours: 0.7001 -0.0299 -4.10% 18:12 05/09 EDT
OPEN
0.6500
PREV CLOSE
0.6560
HIGH
0.7335
LOW
0.6300
VOLUME
270.58K
TURNOVER
--
52 WEEK HIGH
1.880
52 WEEK LOW
0.5231
MARKET CAP
22.66M
P/E (TTM)
-2.7138
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
NASDAQ · 3d ago
Weekly Report: what happened at DRRX last week (0428-0502)?
Weekly Report · 6d ago
Weekly Report: what happened at DRRX last week (0421-0425)?
Weekly Report · 04/28 12:25
Weekly Report: what happened at DRRX last week (0414-0418)?
Weekly Report · 04/21 12:24
Weekly Report: what happened at DRRX last week (0407-0411)?
Weekly Report · 04/14 12:09
Weekly Report: what happened at DRRX last week (0331-0404)?
Weekly Report · 04/07 12:08
Weekly Report: what happened at DRRX last week (0324-0328)?
Weekly Report · 03/31 12:25
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 03/30 08:15
More
About DRRX
More
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has developed a proprietary drug product for the treatment of ADHD called Methydur.
Recently
Symbol
Price
%Change
    RGA
  • 204.85
  • +1.38%

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.